It looks like you are visiting from outside the EU. Switch to the US version to see local pricing in USD and local shipping.

Switch to US ($)
Contact +33 (0)3 90 20 54 70
  • What are the most common targets for ADCs?
    Antibody-drug conjugates

    What are the most common targets for ADCs?

    Thomas Meyer Thomas Meyer 5 min read

    Currently, dozens of antibody-drug conjugates (ADCs) and immunotoxins have reached the clinic or are under active clinical development. These invaluable ADC therapies target a plethora of disease markers. In…

  1. CAR-T cell therapy

    From the first to the fifth generation of CAR-T cells

    Read more
  2. CAR-T cell therapy

    The structure of CAR-T cells

    Read more
  3. Antibody production

    Antibody production: a complete guide

    Read more
  4. Peptide synthesis

    What are the challenges in chemical and recombinant peptide production processes and how to overcome them?

    Read more
  5. Protein production

    A guide to mammalian cell-based expression systems

    Read more

Let’s talk about science – Scientists in the spotlight

Dr. Louisa James

“The COVID-19 pandemic is helping us bridge the divide between virologists and immunologists”

Read more
Queen Mary University of London (QMUL, UK) Queen Mary University of London (QMUL, UK)
“The COVID-19 pandemic is helping us bridge the divide between virologists and immunologists”
Dr. Mara Freire

Reinventing IgY biotherapeutics

Read more
CICECO, University of Aveiro CICECO, University of Aveiro
Reinventing IgY biotherapeutics
Dr. Melanie Conrad

How the environment shapes immune system development during pregnancy

Read more
Charité Medical University in Berlin Charité Medical University in Berlin
How the environment shapes immune system development during pregnancy
Dr. Mohamed Alfaleh

“Cell-based phage display is helping us isolate more biologically relevant antibodies”

Read more
King Abdulaziz University King Abdulaziz University
“Cell-based phage display is helping us isolate more biologically relevant antibodies”
Prof. Tomáš Kalina

“Researchers are not leveraging the speed and resolution of flow cytometry for clinical evaluation”

Read more
Charles University in Prague Charles University in Prague
“Researchers are not leveraging the speed and resolution of flow cytometry for clinical evaluation”
Prof. Richard Pleass

“Antibodies will make a significant contribution to design effective control strategies for COVID-19”

Read more
LSTM LSTM
“Antibodies will make a significant contribution to design effective control strategies for COVID-19”
Professor Istvan Toth

“Simplicity is the key to successful large-scale applications”

Read more
Queensland University, Australia Queensland University, Australia
“Simplicity is the key to successful large-scale applications”
See More

Read by topic

Cart (0 Items)

Your cart is currently empty.

View Products